BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 3315183)

  • 1. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
    van Hennik MB; van der Vijgh WJ; Klein I; Elferink F; Vermorken JB; Winograd B; Pinedo HM
    Cancer Res; 1987 Dec; 47(23):6297-301. PubMed ID: 3315183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
    Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
    Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of carboplatin after i.v. administration.
    Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM
    Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
    Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
    Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin.
    Tosetti F; Rocco M; Fulco RA; Chiara S; Bruzzone M; Campora E; Esposito M
    Anticancer Res; 1988; 8(3):381-6. PubMed ID: 2839099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
    Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
    Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
    Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
    Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics of plasma and cerebrospinal fluid cisplatin in patients with malignant glioma and metastatic brain tumor after selective intraarterial or intravenous and intracarotid administration of etoposide and cisplatin].
    Nakagawa H; Miyawaki Y; Tokiyoshi K; Tsuruzono K; Yamada M; Kanayama T; Hayakawa T
    No Shinkei Geka; 1994 Jan; 22(1):35-42. PubMed ID: 8295700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
    Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
    J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.
    Vermorken JB; van der Vijgh WJ; Klein I; Hart AA; Gall HE; Pinedo HM
    Cancer Treat Rep; 1984 Mar; 68(3):505-13. PubMed ID: 6538459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
    Gamelin E; Bouil AL; Boisdron-Celle M; Turcant A; Delva R; Cailleux A; Krikorian A; Brienza S; Cvitkovic E; Robert J; Larra F; Allain P
    Clin Cancer Res; 1997 Jun; 3(6):891-9. PubMed ID: 9815764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
    Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
    Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.
    Winograd B; Vermorken JB; ten Bokkel Huinink WW; Simonetti G; Gall HE; Knobf MK; van der Vijgh WJ; McVie JG; Pinedo HM
    Cancer Res; 1986 Apr; 46(4 Pt 2):2148-51. PubMed ID: 3948186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
    Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.